Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an ...

Antisense suppression of IGF-I receptors in ... Oligonucleotide sequences corresponded to DNA sequences complementary to the coding region of the IGF type I receptor mRNA 46, with dU substituted ...

As of 10:38:41 AM EDT. Market Open. Loading Chart for DNA ...

Investigators in the laboratory of Gemma Carvill, Ph.D., assistant professor in the Ken and Ruth Davee Department of Neurology Division of Epilepsy/Clinical Neurophysiology, have discovered novel ...

Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Antisense oligonucleotides (ASOs), 2020 - 2035 Figure 05: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Small interfering ...

Natural "off switch" could slow or even reverse the growth of aggressive tumors.

Figure 1: Dnmt1 actively represses transcription using sequences that overlap the HRX repression domain. Figure 2: Dnmt1 686–812 represses transcription in a TSA-sensitive manner and has the ...

BEIJING, China I March 24, 2025 I SineuGene Therapeutics Co., Ltd. ("SineuGene"), a clinical-stage biotech company pioneering innovative therapies for ...

Cancer disrupts RNA splicing by suppressing poison exons, leading to uncontrolled tumor growth. Researchers at JAX and UConn Health found that targeting TRA2β RNA with antisense oligonucleotides (ASOs ...

Antisense oligonucleotide (ASO) technology has accelerated drug discovery in the last few decades with several ASO-based drugs currently approved by FDA and many more being investigated in clinical ...